BAYER AG
π©πͺGermany
- Country
- π©πͺGermany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
Health Economic Evaluation of Primovist-enhanced Liver MRI
Phase 4
Completed
- Conditions
- Colorectal NeoplasmsNeoplasm Metastasis
- Interventions
- Procedure: Extracellular contrast media (ECCM) MRIProcedure: Primovist MRIProcedure: Contrast-enhanced CT
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2014-11-04
- Lead Sponsor
- Bayer
- Target Recruit Count
- 360
- Registration Number
- NCT00764621
Effects of SH T00658ID on Libido
Phase 3
Completed
- Conditions
- LibidoContraception
- Interventions
- Drug: MicrogynonDrug: EV/DNG (Qlaira, BAY86-5027, SH T00658ID)Drug: Placebo
- First Posted Date
- 2008-10-02
- Last Posted Date
- 2014-12-30
- Lead Sponsor
- Bayer
- Target Recruit Count
- 217
- Registration Number
- NCT00764881
- Locations
- π¦πΊ
Royal Adelaide Hospital, Adelaide, South Australia, Australia
π¦πΉClin Pharm International GmbH Studienzentrum Wien, Wien, Austria
π¦πΊSydney Centre for Reproductive Health Reseach, Ashfield, New South Wales, Australia
Pilot Study of Safety and Efficacy of Spheramine
Phase 2
Terminated
- Conditions
- Parkinson''s Disease
- Interventions
- Biological: Spheramine (BAY86-5280)
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2021-04-08
- Lead Sponsor
- Bayer
- Target Recruit Count
- 6
- Registration Number
- NCT00761436
BAY 0 9867 Cipro Pediatric Use Study (QUIP)
Phase 3
Completed
- Conditions
- Infectious Diseases
- Interventions
- Drug: Non-quinolone antibioticDrug: Ciprofloxacin
- First Posted Date
- 2008-09-29
- Last Posted Date
- 2015-07-31
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1029
- Registration Number
- NCT00761462
Pharmacodynamic Characterization of Dienogest
Phase 1
Completed
- Conditions
- Pharmacodynamics
- Interventions
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2015-01-27
- Lead Sponsor
- Bayer
- Target Recruit Count
- 102
- Registration Number
- NCT00754871
Comparative Efficacy of Ovule vs Tablet
Phase 3
Completed
- Conditions
- ClotrimazoleOvulenVulvovaginal Candidiasis
- Interventions
- Drug: Clotrimazole, vaginal tabletDrug: Clotrimazole, vaginal ovule
- First Posted Date
- 2008-09-18
- Last Posted Date
- 2015-08-06
- Lead Sponsor
- Bayer
- Target Recruit Count
- 466
- Registration Number
- NCT00755053
To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)
Phase 3
Completed
- Conditions
- Contraception
- Interventions
- Drug: Ortho Tri Cyclen LoDrug: Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)
- First Posted Date
- 2008-09-17
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Bayer
- Target Recruit Count
- 409
- Registration Number
- NCT00754065
- Locations
- π¨π¦
Regina Medical Centre, Regina, Saskatchewan, Canada
πΊπΈAdam Patterson OB-GYN, Memphis, Tennessee, United States
πΊπΈClinical Research of Philadelphia, LLC, Philadelphia, Pennsylvania, United States
Single/Multiple Dose Bioavailability Trial
Phase 1
Completed
- Conditions
- Healthy
- Interventions
- Drug: Naproxen Sodium 660mgDrug: Commercial Aleve 220 mg
- First Posted Date
- 2008-09-12
- Last Posted Date
- 2014-04-21
- Lead Sponsor
- Bayer
- Target Recruit Count
- 32
- Registration Number
- NCT00751556
Naproxen Sodium Extended-Release Actual Use Study
- First Posted Date
- 2008-09-12
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Bayer
- Target Recruit Count
- 497
- Registration Number
- NCT00751400
Prevention of Sagopilone-induced Neurotoxicity With Acetyl-L-Carnitine (ALC)
Phase 2
Completed
- Conditions
- Ovarian CancerProstate Cancer
- First Posted Date
- 2008-09-11
- Last Posted Date
- 2014-10-28
- Lead Sponsor
- Bayer
- Target Recruit Count
- 150
- Registration Number
- NCT00751205
Β© Copyright 2025. All Rights Reserved by MedPath